A Phase II Study of Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2015
At a glance
- Drugs Algenpantucel-L (Primary) ; Fluorouracil; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors NewLink Genetics Corporation
- 03 Jun 2014 According to a NewLink Genetics media release, results from this study presented at the 50th Annual Meeting of American Society of Clinical Oncology.
- 19 Jun 2012 Status changed from active, no longer recruiting to completed, according to a NewLink Genetics Corporation media release.
- 04 Jun 2012 Results have been presented at ASCO-2012 according to a NewLink Genetics media release. Results were also summarised in the media release.